Participated · Series B · Jun 2026

Ona Therapeutics is a spin-off from IRB Barcelona and ICREA that develops precision-engineered antibody-drug conjugates (ADCs) to target treatment-resistant cancers. The company uses a proprietary, patient-driven discovery platform to identify tumor-specific antigens and epitopes that enable efficient internalization and targeted payload delivery. Its lead clinical program is ONA-255, initially focused on breast cancer, and it is also advancing ONA-389 targeting colorectal cancer. The company integrates target validation, antibody engineering, optimized payload selection and validated linker-payload technologies in its ADC development approach. Led by CEO Valerie Vanhooren, Ona plans to use the Series B proceeds to advance clinical development of its lead and second programs. The article does not disclose revenue, user metrics or a company valuation.

Led · Equity · Mar 2026

Peptomyc was founded in 2014 as a spin-off supported by the Vall d'Hebron Institute of Oncology (VHIO) and Icrea and is based in Barcelona. The company is developing Omomyc, a biologic designed to inhibit the oncogene Myc, which its cofounder Laura Soucek has studied for decades. Peptomyc completed an initial clinical trial in patients with solid tumors and is currently running studies targeting pancreatic cancer and osteosarcoma. The recent €5 million financing will fund completion of those clinical programs. The company has indicated it may pursue a partnership with a pharmaceutical firm to accelerate development and commercialization. Public and institutional backers such as CDTI and the EIC Fund are among its current supporters.

Participated · Series B · Oct 2022

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.

Participated · Equity · Oct 2021

Mediktor provides an AI-powered symptom triage tool that helps patients perform self-triage and assists healthcare professionals. The platform is available in 15 languages and can be integrated into websites, mobile apps and chatbots. Mediktor serves clients including insurers such as Mapfre and DKV and private healthcare groups. The company operates a B2B model for insurers, hospitals, telemedicine platforms and pharmaceutical firms. It closed 2020 with €1.5M in revenue, with 60% of income from Europe, 30% from Latin America and 10% from the United States. Mediktor plans to use new funds to accelerate international expansion and to further refine its triage tools, and it operates offices in Barcelona and New York. Mediktor develops an artificial intelligence application for health that provides prediagnosis and patient classification, and it collaborates with Hospital Clínic de Barcelona. The company reports a 91.3% success rate in prediagnosis and classification of patients. Founded in 2011 in Barcelona, Mediktor opened its first international office in New York in May 2017. Its product is positioned for clinical and consumer use, and the company is focused on commercial expansion. The funds raised will be used to support commercialization efforts in the North American market. No revenue or user figures were disclosed in the articles.

Participated · Series E · May 2021

Binx Health is a medical technology and diagnostic services provider. The company supplies testing, diagnostic and treatment services to clinics using its binx io testing instrument and a cartridge-based system. The binx io instrument and its cartridge are presented as the company’s core diagnostic products. According to the article, Binx Health recently completed a $65 million Series F financing. The reported financing round involved outside investors led by Hildred Capital with participation from EQT Life Sciences. binx health develops the binx io rapid molecular point-of-care testing platform, a CLIA‑waived solution that enables testing, diagnosis and treatment for chlamydia and gonorrhea during the same visit. The company supplies in‑clinic and at‑retail locations with its testing instrument and single‑use cartridges and is led by CEO Jeff Luber. It is expanding the platform into COVID‑19 testing by combining proprietary electrochemical detection with CRISPR methods. binx health plans to use recent funding to ramp manufacturing, scale its instrument and cartridges, expand sales in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure. The company describes itself as a healthcare technology and diagnostics firm focused on rapid molecular point‑of‑care testing. Atlas Genetics is a Bath, England–based company that develops ultra-rapid point-of-care (POC) molecular diagnostic tests for infectious diseases. Its io® system is a molecular diagnostic platform built on a patent-protected electrochemical sensor technology. The system uses an integrated cartridge containing all reagents designed to accept an unprocessed clinical specimen; each cartridge can detect up to 24 different genetic targets. The company plans to use recent financing to support clinical trials and the commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, targeting US regulatory approvals around the end of 2017. Atlas also intends to further develop its diagnostics menu and expand cartridge manufacturing capacity at Bespak. The company maintains a commercial office in Boston and is led by CEO Dr. John Clarkson. The firm reported closing a $35m Series D to fund these activities. Atlas Genetics develops the io(R) system, a novel point-of-care molecular diagnostic platform based on a patent‑protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated cartridge contains all reagents, accepts an unprocessed clinical specimen and completes sample preparation, DNA amplification and electrochemical detection. Each cartridge can run up to 24 different tests from a single patient sample. The system is at an advanced stage of development and is expected to launch in Europe with a Chlamydia test later this year. The company plans to use the new funding to launch the io(R) system, initiate U.S. clinical trials and expand its test menu in STI and HAI markets. Atlas is led by CEO Dr John Clarkson. Atlas Genetics develops rapid decentralized and point-of-care (POC) molecular diagnostic tests for a range of infectious diseases, including sexually transmitted and hospital-acquired infections. Its Atlas io™ system is a patented electrochemical sensor–based molecular diagnostic platform that combines speed and accuracy while removing the need for costly optical components. The company is led by CEO Dr John Clarkson. Atlas intends to use the new funding to complete the transfer to manufacture of the Atlas io™ system and to file for European approval of its first Chlamydia test. The article reports a Series B financing, reflecting an active fundraising stage to support product commercialization and regulatory approval.